Biomarkers are revolutionizing the treatment landscape for NSCLC

Martin Reck, MD, PhD from the Lungen Clinic Grosshansdorf, Grosshandsdorf, Germany explains the role of biomarkers in precision medicine for non-small cell lung cancer (NSCLC). The development of biomarkers has changed the landscape for NSCLC, as they are crucial in the development of novel drug therapies through the discovery of potential targets. In addition, biomarkers can be prognostic and predictive of disease outcomes. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.

Share this video